Cargando…

Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia

IMPORTANCE: The most prescribed class of medications for benign prostatic hyperplasia (BPH) is α-blockers (ABs). However, the cardiovascular safety profile of these medications among patients with BPH is not well understood. OBJECTIVE: To compare the safety of ABs vs 5-α reductase inhibitors (5-ARIs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jiandong, Latour, Chase D., Olawore, Oluwasolape, Pate, Virginia, Friedlander, David F., Stürmer, Til, Jonsson Funk, Michele, Jensen, Brian C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646730/ https://www.ncbi.nlm.nih.gov/pubmed/37962887 http://dx.doi.org/10.1001/jamanetworkopen.2023.43299

Ejemplares similares

α-Blocker Monotherapy and α-Blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years' Long-Term Results
por: Shin, Teak Jun, et al.
Publicado: (2012)

Effect of Shifting from Combination Therapy to Monotherapy of α-Blockers or 5α-Reductase Inhibitors on Prostate Volume and Symptoms in Patients with Benign Prostatic Hyperplasia
por: Kim, Hyoung Woo, et al.
Publicado: (2011)

Long-term Combination Therapy With α-Blockers and 5α-Reductase Inhibitors in Benign Prostatic Hyperplasia: Patient Adherence and Causes of Withdrawal From Medication
por: Ong, Hueih Ling, et al.
Publicado: (2016)

α1-Blockers and 5α-Reductase Inhibitors Are the Most Recommended Drugs in Treating Benign Prostatic Hyperplasia: An Evidence-Based Evaluation of Clinical Practice Guidelines
por: Xu, Xiao-Feng, et al.
Publicado: (2020)

Ramelteon combined with an α(1)-blocker decreases nocturia in men with benign prostatic hyperplasia
por: Kawahara, Takashi, et al.
Publicado: (2013)

Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination
por: Shum, Cheuk Fan, et al.
Publicado: (2017)

5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer
por: Robinson, David, et al.
Publicado: (2015)

Personalized therapeutics of α(1)-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
por: Zhu, Ling-ling, et al.
Publicado: (2015)

Cinnamomi Cortex (Cinnamomum verum) Suppresses Testosterone-induced Benign Prostatic Hyperplasia by Regulating 5α-reductase
por: Choi, Hyun-Myung, et al.
Publicado: (2016)

Pao Pereira Extract Attenuates Testosterone-Induced Benign Prostatic Hyperplasia in Rats by inhibiting 5α-Reductase
por: Liu, Jiakuan, et al.
Publicado: (2019)

Seasonal Changes in Lower Urinary Tract Symptoms in Japanese Men With Benign Prostatic Hyperplasia Treated With α(1)-Blockers
por: Kobayashi, Minoru, et al.
Publicado: (2017)

A Dual 5α-Reductase Inhibitor Dutasteride Caused Reductions in Vascular Density and Area in Benign Prostatic Hyperplasia
por: Zaitsu, Masayoshi, et al.
Publicado: (2013)

A meta-analysis of the vascular-related safety profile and efficacy of α-adrenergic blockers for symptoms related to benign prostatic hyperplasia
por: Nickel, J C, et al.
Publicado: (2008)

Patterns of Rotavirus Vaccine Uptake and Use in Privately-Insured US Infants, 2006–2010
por: Panozzo, Catherine A., et al.
Publicado: (2013)

Combined effect of polymorphisms in type III 5-α reductase and androgen receptor gene with the risk of benign prostatic hyperplasia in Korea
por: Lee, Chung Lyul, et al.
Publicado: (2016)

Corni Fructus attenuates testosterone-induced benign prostatic hyperplasia by suppressing 5α-reductase and androgen receptor expression in rats
por: Hwangbo, Hyun, et al.
Publicado: (2018)

Upregulation of mir-1199-5p is associated with reduced type 2 5-α reductase expression in benign prostatic hyperplasia
por: Liu, Zhanliang, et al.
Publicado: (2022)

5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data
por: Del Giudice, Francesco, et al.
Publicado: (2023)

Chrysophanic acid reduces testosterone-induced benign prostatic hyperplasia in rats by suppressing 5α-reductase and extracellular signal-regulated kinase
por: Youn, Dong-Hyun, et al.
Publicado: (2016)

Effect of 5α-reductase inhibitors on the efficiency of thulium:yttrium-aluminium-garnet (RevoLix®) vaporesection for treating benign prostatic hyperplasia
por: Chung, Jae Seung, et al.
Publicado: (2020)

Trapa bispinosa Roxb. Pericarp Extract Exerts 5α-Reductase Inhibitory Activity in Castrated Benign Prostatic Hyperplasia Model Mice
por: Fujita, Takashi, et al.
Publicado: (2023)

Comparative Propensity-Weighted Mortality After Isolated Acute Traumatic Axis Fractures in Older Adults
por: Catalino, Michael P., et al.
Publicado: (2020)

Cynanchum wilfordii Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Regulating 5α-Reductase and Androgen Receptor Activities in a Rat Model
por: Lee, Gyuok, et al.
Publicado: (2017)

The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
por: Kim, Eric H., et al.
Publicado: (2018)

Effect of α-receptor blockers on lower urinary tract symptoms, sexual function and quality of life in young and middle-aged men with benign prostatic hyperplasia
por: Wang, Tongqing, et al.
Publicado: (2017)

Prospective Factor Analysis of Alpha Blocker Monotherapy Failure in Benign Prostatic Hyperplasia
por: Hong, Kyoung Pyo, et al.
Publicado: (2010)

Impact of preoperative 5α-reductase inhibitors on perioperative blood loss in patients with benign prostatic hyperplasia: a meta-analysis of randomized controlled trials
por: Zhu, Yi-Ping, et al.
Publicado: (2015)

Mixture of Corni Fructus and Schisandrae Fructus improves testosterone-induced benign prostatic hyperplasia through regulating 5α-reductase 2 and androgen receptor
por: Hwangbo, Hyun, et al.
Publicado: (2023)

Sinomenine Hydrochloride Can Ameliorate Benign Prostatic Hyperplasia by Lowering the 5α-Reductase 2 Level and Regulating the Balance between the Proliferation and Apoptosis of Cells
por: Fan, Mao-Si, et al.
Publicado: (2023)

Depression risk associated with the use of 5α-reductase inhibitors versus α-blockers: A retrospective cohort study in South Korea
por: Yeon, Bora, et al.
Publicado: (2022)

The comparative risk of acute kidney injury of vancomycin relative to other common antibiotics
por: Gaggl, Martina, et al.
Publicado: (2020)

Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier’s gangrene
por: Yang, Jeff Yufeng, et al.
Publicado: (2020)

Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia
por: Cho, Kang Jun, et al.
Publicado: (2011)

Clinical Effects of Discontinuing 5-Alpha Reductase Inhibitor in Patients With Benign Prostatic Hyperplasia
por: Kim, Won, et al.
Publicado: (2014)

Prescription pattern of alpha-blockers for management of lower urinary tract symptoms/benign prostatic hyperplasia
por: Moon, Hyong Woo, et al.
Publicado: (2018)

Cardiovascular Effectiveness of Sodium‐Glucose Cotransporter 2 Inhibitors and Glucagon‐Like Peptide‐1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure
por: Htoo, Phyo T., et al.
Publicado: (2022)

Protective effects of combination of Stauntonia hexaphylla and Cornus officinalis on testosterone-induced benign prostatic hyperplasia through inhibition of 5α- reductase type 2 and induced cell apoptosis
por: Karunasagara, Shanika, et al.
Publicado: (2020)

Gender Disparities in Surgical Treatment of Axis Fractures in Older Adults
por: Catalino, Michael P., et al.
Publicado: (2019)

Alpha-1 blockers and susceptibility to COVID-19 in benign prostate hyperplasia patients : an international cohort study
por: Nishimura, Akihiko, et al.
Publicado: (2021)

CNS Demyelination with TNF-α Blockers
por: Kemanetzoglou, Elissavet, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4joeflete7vvtsrfhoufesuoir